In a Spanish cohort, MODY-X patients, in comparison with MODY2 or MODY3, presented higher levels of hyperglycemia and reduced insulin sensitivity, whereas, in a French study population, MODY-X individuals displayed a less aggressive clinical course than their counterparts affected by MODY3 [19]. This evidence concerns the gene INS and Hyperglycemia.